16 terminated. 16 Phase 2, 8 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Terminated 16 |
| Phase 1 | 8 | Terminated 8 |
| Phase 3 | 1 | Terminated 1 |
Follow Mucinoses: new trials by email Literature Review of Mucinoses trials Research Report on Mucinoses
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Continuation Study of Long-term Safety, Tolerability, Pharmacokinetics and Efficacy of Recifercept in Achondroplasia Recifercept - Achondroplasia | Phase 2 | Terminated | Pfizer | 35 | 2021-12-24 | 2024-02-08 |
| A Study Of Safety, Tolerability And Effectiveness Of Recifercept In Children With Achondroplasia Recifercept - Achondroplasia | Phase 2 | Terminated | Pfizer | 60 | 2020-12-02 | 2024-02-15 |
| Gene Transfer Study of ABO-102 in Patients With Middle and Advanced Phases of MPS IIIA Disease ABO-102 - MPS IIIA, Sanfilippo Syndrome | Phase 1 / Phase 2 | Terminated | Ultragenyx Pharmaceutical Inc | 5 | 2019-09-18 | 2023-07-25 |
| Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIB rAAV9.CMV.hNAGLU - Mucopolysaccharidosis Type 3 B | Phase 1 / Phase 2 | Terminated | Abeona Therapeutics, Inc | 11 | 2017-10-16 | 2022-05-05 |
| Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I SB-318 - MPS I | Phase 1 / Phase 2 | Terminated | Sangamo Therapeutics | 3 | 2017-05-24 | 2023-01-26 |
| Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II SB-913 - Mucopolysaccharidosis II, MPS II | Phase 1 / Phase 2 | Terminated | Sangamo Therapeutics | 9 | 2017-05-11 | 2022-10-25 |
| A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously SBC-103 - Mucopolysaccharidosis III, Type B (MPS IIIB), Sanfilippo B | Phase 1 / Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 3 | 2015-10-15 | 2018-04-17 |
| An Extension Study to Determine Safety and Efficacy for Pediatric Patients With MPS Type IIIA Disease Who Participated in Study HGT-SAN-093. HGT-1410 - Sanfilippo Syndrome, Mucopolysaccharidosis (MPS) | Phase 2 | Terminated | Shire | 17 | 2015-04-08 | 2021-06-11 |
| Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation BMN 110 - Mucopolysaccharidosis IVA, Morquio A Syndrome | Phase 2 | Terminated | BioMarin Pharmaceutical | 16 | 2012-08-01 | 2016-01-12 |
| Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome BMN 110 - Mucopolysaccharidosis IVA, Morquio A Syndrome | Phase 2 | Terminated | BioMarin Pharmaceutical | 25 | 2012-04-01 | 2016-02-01 |
| Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders hematopoietic stem cell infusion - Hurler Syndrome (MPS I), Hurler-Scheie Syndrome | Phase 1 / Phase 2 | Terminated | Talaris Therapeutics Inc. | 3 | 2011-04-01 | 2023-04-12 |
| Extension of Study HGT-SAN-055 Evaluating Administration of rhHNS in Patients With Sanfilippo Syndrome Type A (MPS IIIA) rhHNS-10 mg, rhHNS-45 mg, rhHNS-90 mg - Sanfilippo Syndrome | Phase 1 / Phase 2 | Terminated | Shire | 12 | 2011-03-01 | 2021-06-14 |
| A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) BMN 110 - MPS IV A, Mucopolysaccharidosis IVA | Phase 1 / Phase 2 | Terminated | BioMarin Pharmaceutical | 20 | 2010-11-01 | 2015-09-30 |
| Clinical Trial of Growth Hormone in MPS I, II, and VI Somatropin (DNA origin) - Mucopolysaccharidosis I, Mucopolysaccharidosis II | Phase 2 / Phase 3 | Terminated | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | 2 | 2008-11-01 | 2018-09-05 |
| Study of AAV-GAD Gene Transfer Into the Subthalamic Nucleus for Parkinson's Disease Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus - Parkinson's Disease | Phase 2 | Terminated | Neurologix, Inc. | 44 | 2008-08-01 | 2012-02-22 |
| Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism Stem Cell Transplantation, Cyclophosphamide, Campath-1H - Hurler's Syndrome, Maroteaux-Lamy Syndrome | Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 18 | 2008-03-01 | 2017-12-28 |
Mucopolysaccharidosis III (6) · Mucopolysaccharidosis IV (5) · Lysosomal Storage Diseases (4) · Mucopolysaccharidosis I (4) · Mucopolysaccharidosis II (3) · Sudden Infant Death (3) · Achondroplasia (2) · Dwarfism (2) · Leukodystrophy, Globoid Cell (2) · Leukodystrophy, Metachromatic (2) · Mucopolysaccharidosis VI (2) · alpha-Mannosidosis (2) · Adrenoleukodystrophy (1) · Aspartylglucosaminuria (1) · Basal Ganglia Diseases (1)
Connective Tissue Diseases (16) · Skin and Connective Tissue Diseases (16) · Carbohydrate Metabolism, Inborn Errors (15) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (15) · Metabolic Diseases (15) · Nutritional and Metabolic Diseases (15) · Genetic Diseases, Inborn (14) · Metabolism, Inborn Errors (14) · Mucopolysaccharidoses (14) · Lysosomal Storage Diseases (11) · Nervous System Diseases (4) · Bone Diseases, Developmental (3) · Death (3) · Death, Sudden (3)
GALNS protein, human (3) · Chondroitinases and Chondroitin Lyases (2) · Enzyme Replacement Therapy (2) · Galns protein, mouse (2) · Stem Cell Transplantation (2) · Sulfatases (2) · Alemtuzumab (1) · Bone Marrow Transplantation (1) · Busulfan (1) · Cyclophosphamide (1) · Growth Hormone (1) · Human Growth Hormone (1)
BioMarin Pharmaceutical (3) · Pfizer (2) · Sangamo Therapeutics (2) · Shire (2) · Abeona Therapeutics, Inc (1) · Alexion Pharmaceuticals, Inc. (1) · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (1) · Masonic Cancer Center, University of Minnesota (1) · Neurologix, Inc. (1) · Talaris Therapeutics Inc. (1) · Ultragenyx Pharmaceutical Inc (1)
United States (13) · United Kingdom (6) · Spain (5) · Germany (4) · Australia (3) · Italy (3) · Belgium (2) · Denmark (2) · France (2) · Netherlands (2) · Portugal (2) · Canada (1) · Japan (1)
Adam Shaywitz, MD PhD (1) · Celeste Decker, M.D. (1) · Celeste Decker, MD (1) · Lynda E Polgreen, M.D. (1) · Paul Orchard, MD (1) · Suzanne T Ildstad, MD (1)
PMID 36299240, PMID 21419704, PMID 21586746, PMID 22547151, PMID 25421091, PMID 28405611, PMID 29159458, PMID 29526614, PMID 32278382, PMID 32884151, PMID 34600820, PMID 38685585
2014 (1), 2015 (1), 2018 (1)